Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain-Reference-Cited by-同舟云学术

Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

Published:2019-07-24 Issue:502 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Burke James R.¹^ORCID,Cheng Lihong¹,Gillooly Kathleen M.¹,Strnad Joann¹,Zupa-Fernandez Adriana¹^ORCID,Catlett Ian M.²^ORCID,Zhang Yifan¹,Heimrich Elizabeth M.¹^ORCID,McIntyre Kim W.¹^ORCID,Cunningham Mark D.³^ORCID,Carman Julie A.³^ORCID,Zhou Xiadi¹,Banas Dana³^ORCID,Chaudhry Charu⁴,Li Sha⁴,D’Arienzo Celia⁵,Chimalakonda Anjaneya⁵,Yang XiaoXia¹,Xie Jenny H.¹^ORCID,Pang Jian¹,Zhao Qihong¹,Rose Shawn M.²,Huang Jinwen¹,Moslin Ryan M.⁶^ORCID,Wrobleski Stephen T.⁶^ORCID,Weinstein David S.⁶^ORCID,Salter-Cid Luisa M.¹

Affiliation:

1. Immunosciences Discovery Biology, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA.

2. Innovative Medicines Development, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA.

3. Translational Medicine, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA.

4. Leads Discovery and Optimization, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA.

5. Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA.

6. Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA.

Abstract

An allosteric TYK2 inhibitor ameliorates disease in murine autoimmune models and blocks type I interferon responses in humans.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference50 articles.

1. A protein tyrosine kinase in the interferon αβ signaling pathway

2. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock

3. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity

4. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility

5. TYK2 Protein-Coding Variants Protect against Rheumatoid Arthritis and Autoimmunity, with No Evidence of Major Pleiotropic Effects on Non-Autoimmune Complex Traits

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis;Pharmaceutics;2024-02-06

2. Emerging biologic therapies for systemic lupus erythematosus;Current Opinion in Rheumatology;2024-02-02

3. Structure-property Relationships Reported for the New Drugs Approved in 2022;Mini-Reviews in Medicinal Chemistry;2024-02

4. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial;The Journal of Dermatology;2024-01-24

5. Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease;International Immunopharmacology;2024-01